Cue Biopharma Total Assets Growth & History (CUE)
Cue Biopharma's total assets was $42.2M for fiscal 2025.
View full Cue Biopharma company overviewCue Biopharma annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.2M | $10.0M | +31.13% |
| 2024 | 2024-12-31 | $32.2M | −$29.3M | −47.68% |
| 2023 | 2023-12-31 | $61.5M | −$29.8M | −32.59% |
| 2022 | 2022-12-31 | $91.3M | $7.9M | +9.45% |
| 2021 | 2021-12-31 | $83.4M | −$16.1M | −16.21% |
| 2020 | 2020-12-31 | $99.5M | $27.9M | +39.00% |
| 2019 | 2019-12-31 | $71.6M | $26.2M | +57.85% |
| 2018 | 2018-12-31 | $45.4M | −$21.6M | −32.25% |
| 2017 | 2017-12-31 | $67.0M | — | — |
Cue Biopharma quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $30.7M | −$10.0M | −24.57% |
| Q1 2026 | 2026-03-31 | $30.9M | $8.6M | +38.75% |
| Q4 2025 | 2025-12-31 | $42.2M | $10.0M | +31.13% |
| Q3 2025 | 2025-09-30 | $31.6M | −$13.2M | −29.38% |
| Q2 2025 | 2025-06-30 | $40.7M | −$1.6M | −3.83% |
| Q1 2025 | 2025-03-31 | $22.3M | −$31.7M | −58.75% |
| Q4 2024 | 2024-12-31 | $32.2M | −$29.3M | −47.68% |
| Q3 2024 | 2024-09-30 | $44.8M | −$24.1M | −34.95% |
| Q2 2024 | 2024-06-30 | $42.3M | −$30.8M | −42.14% |
| Q1 2024 | 2024-03-31 | $54.0M | −$27.7M | −33.95% |
| Q4 2023 | 2023-12-31 | $61.5M | −$29.8M | −32.59% |
| Q3 2023 | 2023-09-30 | $68.9M | −$7.4M | −9.71% |
| Q2 2023 | 2023-06-30 | $73.2M | −$11.6M | −13.67% |
| Q1 2023 | 2023-03-31 | $81.7M | −$9.0M | −9.95% |
| Q4 2022 | 2022-12-31 | $91.3M | $7.9M | +9.45% |
| Q3 2022 | 2022-09-30 | $76.3M | −$2.6M | −3.26% |
| Q2 2022 | 2022-06-30 | $84.7M | −$4.9M | −5.49% |
| Q1 2022 | 2022-03-31 | $90.7M | $2.0M | +2.24% |
| Q4 2021 | 2021-12-31 | $83.4M | −$16.1M | −16.21% |
| Q3 2021 | 2021-09-30 | $78.9M | −$27.7M | −26.02% |
| Q2 2021 | 2021-06-30 | $89.7M | −$11.7M | −11.53% |
| Q1 2021 | 2021-03-31 | $88.7M | $28.1M | +46.29% |
| Q4 2020 | 2020-12-31 | $99.5M | $27.9M | +39.00% |
| Q3 2020 | 2020-09-30 | $106.6M | $61.4M | +135.83% |
| Q2 2020 | 2020-06-30 | $101.4M | $59.6M | +142.73% |
| Q1 2020 | 2020-03-31 | $60.6M | $15.5M | +34.21% |
| Q4 2019 | 2019-12-31 | $71.6M | $26.2M | +57.85% |
| Q3 2019 | 2019-09-30 | $45.2M | $627,000 | +1.41% |
| Q2 2019 | 2019-06-30 | $41.8M | −$11.4M | −21.38% |
| Q1 2019 | 2019-03-31 | $45.2M | −$14.1M | −23.83% |
| Q4 2018 | 2018-12-31 | $45.4M | −$21.6M | −32.25% |
| Q3 2018 | 2018-09-30 | $44.6M | — | — |
| Q2 2018 | 2018-06-30 | $53.1M | — | — |
| Q1 2018 | 2018-03-31 | $59.3M | — | — |
| Q4 2017 | 2017-12-31 | $67.0M | — | — |
Cue Biopharma total assets trends
Over the last five fiscal years, Cue Biopharma's total assets decreased from $99.5M to $42.2M, a change of −$57.3M. The latest reported quarter, Q2 2026, shows $30.7M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cue Biopharma source filings ↗